TOKYO -- Takeda Pharmaceutical on Thursday said it will sell its dry-eye drug business to Swiss rival Novartis for up to $5.3 billion.
The Xiidra dry-eye medication business is owned by Shire, which Takeda bought for 6.2 trillion yen ($56.4 billion) in January.
